Axogen Inc. Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration (FDA) for Avance Nerve Graft® May 16, 2024
Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024 Apr 16, 2024
Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024 Feb 13, 2024
Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap Jan 18, 2024
